<SEC-DOCUMENT>0001193125-23-088389.txt : 20230403
<SEC-HEADER>0001193125-23-088389.hdr.sgml : 20230403
<ACCEPTANCE-DATETIME>20230331174557
ACCESSION NUMBER:		0001193125-23-088389
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230403
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23789471

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d477120d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated March 31, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d477120dex991.htm">Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European
Lung Cancer Congress 2023 </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March 31, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d477120dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g477120dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Positive Final Data in 2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Line Metastatic NSCLC Patients </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Refractory to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-(L)1</FONT></FONT> Therapy at European Lung Cancer
Congress 2023 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to
typical <FONT STYLE="white-space:nowrap">6-9</FONT> months mOS and a <FONT STYLE="white-space:nowrap">10-15%</FONT> OS rate for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> chemotherapy
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">83% of patients studied for Tumour Growth Kinetics showed deceleration of tumour growth or shrinkage of tumours,
previously increasing under <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> monotherapy or in combination with chemotherapy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ORR of 8.3%, DCR of 33.3%, and <FONT STYLE="white-space:nowrap">6-month</FONT> PFS rate of 25% in <FONT
STYLE="white-space:nowrap">all-comer</FONT> <FONT STYLE="white-space:nowrap">PD-L1</FONT> patient population, with most of these <FONT STYLE="white-space:nowrap">PD-X</FONT> refractory patients (75%) having negative or low <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ORR of 33.3%, <FONT STYLE="white-space:nowrap">6-month</FONT> PFS of 50%, and mOS not yet reached for patients
with high <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combination of efti plus pembrolizumab well tolerated in this <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> patient population without any new safety signals </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA
&#150; 31</B><B></B><B>&nbsp;March </B><B>2023 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and
autoimmune disease, today announces positive final data from Part B of the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II trial in 2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> line metastatic
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC) patients refractory to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> therapy via a Mini Oral presentation at ESMO&#146;s
European Lung Cancer Congress (ELCC) 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The presentation by Margarita Majem, M.D., Ph.D., Department of Medical Oncology, Hospital de la Santa Creu i
Sant Pau, titled &#147;<I>Final data from a phase II study <FONT STYLE="white-space:nowrap">(TACTI-002)</FONT> of eftilagimod alpha (soluble <FONT STYLE="white-space:nowrap">LAG-3)</FONT> &amp; pembrolizumab 2</I><I><SUP
STYLE="font-size:75%; vertical-align:top">nd</SUP></I><I> line metastatic NSCLC patients resistant to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> inhibitors&#148; </I>discusses how eftilagimod alpha, a
soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein, targets a subset of MHC class II molecules found on antigen-presenting cells (e.g., dendritic cells, monocytes) to mediate their activation and subsequent CD8<SUP
STYLE="font-size:75%; vertical-align:top">+</SUP> T cell activation/proliferation. This unique stimulation of antigen-presenting cells (APC) leads to a broad anti-tumour immune response, and the addition of efti to pembrolizumab may help refractory
2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> line NSCLC patients that have few therapeutic options by reverting their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> resistance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Majem stated, &#147;In this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> patient population,
these clinical results beneficially show that subcutaneous administration of eftilagimod alpha in combination with pembrolizumab is safely stimulating a broad immune response that may revert resistance to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-X</FONT></FONT> therapy. The data supports further clinical investigation of eftilagimod alpha in combination with pembrolizumab for patients with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> refractory <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer that have limited treatment options.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All patients (N=36) had confirmed progression (e.g., two consecutive scans) after
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> 1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> line treatment with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-X</FONT></FONT> therapy, including 67% that received <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-X</FONT></FONT> therapy and chemotherapy (72%
when excluding <FONT STYLE="white-space:nowrap">non-evaluable</FONT> patients). In these <FONT STYLE="white-space:nowrap">PD-X</FONT> refractory, 2L metastatic NSCLC patients, the chemo-free combination of efti plus pembrolizumab achieved a median
Overall Survival (mOS) of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical <FONT STYLE="white-space:nowrap">6-9</FONT> months mOS and a <FONT STYLE="white-space:nowrap">10-15%</FONT> OS rate at 21 months for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> chemotherapy. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g477120dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, Tumour Growth Kinetics (TGK) analysis looking at the difference of the sum of the largest
diameters of target lesions in the <FONT STYLE="white-space:nowrap">pre-</FONT> and post-baseline setting was performed on patients with data available on the same lesions from prior failed therapy and post-baseline (N=24). 83.3% of patients showed
shrinkage (33%) or deceleration of tumour growth (50%). Notably, 36%, 39%, and 16.7% of patients had a <FONT STYLE="white-space:nowrap">PD-L1</FONT> Tumour Proportion Score (TPS) of &lt;1%, <FONT STYLE="white-space:nowrap">1-49%,</FONT> and
<U>&gt;</U>50%, respectively, and 8.3% of patients were not evaluable for <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti plus
pembrolizumab had an ORR of 8.3%, a DCR of 33%, and a <FONT STYLE="white-space:nowrap">6-month</FONT> PFS rate of 25% in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">all-comerPD-L1</FONT></FONT> patient population, with most
of these <FONT STYLE="white-space:nowrap">PD-X</FONT> refractory patients (75%) having negative or low <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. The ORR, PFS, and OS were more pronounced in patients with high <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression (N=6) or who were secondary resistant (N=25). For patients with &#8805;50% <FONT STYLE="white-space:nowrap">PD-L1</FONT> TPS expression, mOS was not yet reached, ORR was 33.3%, and <FONT
STYLE="white-space:nowrap">6-month</FONT> PFS was 50%. Efti plus pembrolizumab was well tolerated without any new safety signals, and there was no treatment discontinuation due to adverse reactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep CSO and CMO, Dr Frederic Triebel, noted: &#147;The maturation of data across all three indications in the
<FONT STYLE="white-space:nowrap">all-comer</FONT> <FONT STYLE="white-space:nowrap">TACTI-002</FONT> trial, namely 1st line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, 2nd line head and neck cancer, and 2nd line <FONT
STYLE="white-space:nowrap">PD-X</FONT> refractory <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, has continued to strengthen our belief that combining immunotherapies that harness the power of both innate and adaptive immunity
may be very effective in fighting cancer. Efti&#146;s unique targeting and activation of antigen-presenting cells has shown a promising benefit with checkpoint inhibitors that target T cells, and we believe the combination of efti and pembrolizumab
has significant potential to safely improve outcomes for cancer patients.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep CEO, Marc Voigt, concluded, &#147;These encouraging results and
overall survival trends in patients refractory to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> containing therapy, which have confirmed progression via two consecutive scans, offers a potential
therapeutic pathway for many in dire need of new options. As we assess this potential, we continue to focus our late-stage clinical development of efti in combination with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy in 1st line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and 1st line head and neck cancer and look forward to providing more
details on both as the year progresses.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Mini Oral presentation will be available on the Posters&nbsp;&amp; Publications section of
<U>Immutep&#146;s website.</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> clinical stage candidate that is a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator that stimulates both innate and adaptive immunity for the treatment of cancer. Efti binds to and activates antigen-presenting cells via MHC II molecules
leading to expansion and proliferation of CD8<SUP STYLE="font-size:75%; vertical-align:top">+ </SUP>(cytotoxic) T cells, CD4<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> (helper) T cells, dendritic cells, NK cells, and monocytes. It also
upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy
and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g477120dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to market for patients in need and to maximise value for shareholders. For more
information, please visit <U>www.immutep.com.</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264
George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g477120dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g477120dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MNG4A5@ITFI0ELU_6GH:0_E^E7L:+\@H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@!"<?A_D4 ?%&M_M'>-]/^/47PVM_"=G+X>_M^PT,JUOJ
M(UVXM[MX(I-;MYUF$(@C,QF1?LKH8806D!)EB /M9,[1G@]_:@!U !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MU:TA$]QI-_L$X@#*AN+:6(F.YA5V56*D,A9=Z*&4GOPF,HXN/N/EDE?EO?\
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M[6RW#7=Q>7D @4&ZBQL64D;CMXH ^;Y?V[=+27%M\-[^6'/WYO$]M;R[0?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 U^GXC^=-;K^N@UU]&?FUXA_P"2^3_]E#L?_3I:U\M7_P"1
ME5_QK\S\FQ/_ "4;_P"PB/\ Z4>X?M4_\@#PG_V%KW_TC6N_.?X5'^NA]'QO
M_N-#_K['_P!-5#T#]G3CX7:/[7FL_P#ISN*Z<M_W2E_B_P STN%M,GI^K_4^
M:OVF?^2EK_V+VE?I/J%>9F/^^4_(^2XO7_"OAG_T[_\ ;D?=GAC_ )%OP_\
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M3W\>H:R$=60BVU74KJ[L6VL,@/8O;OC_ &_S-O(-O(^@: "@ H * "@ H *
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MEHSC('!Z5[%.+4(K9Q6WX'UE"E.G0I0:7-3@HVOV26]M-CY6A^!OC"+XI?\
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M0+B/(+@=>37BT<!5HXM5V_=C)R2M:]^A\9AN',90S=8V<H^SYW)):_C?]#Z
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#QH?'[X5?\ 0T)Q
M_P!0K7/_ )65PK,<)_S\M8\'_63*4E^__ /^%_?"G_H:%_\ !5KG_P K*?\
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M /@'_"_OA3_T-"_^"K7/_E91_:.#_P"?OX!_K)E/_/\ _ /^%_?"G_H:%_\
M!5KG_P K*/[1P?\ S]_ /]9,I_Y__@'_  O[X4_]#0O_ (*M<_\ E91_:.#_
M .?OX!_K)E/_ #__  #_ (7]\*?^AH7_ ,%6N?\ RLH_M'!_\_?P#_63*?\
MG_\ @'_"_OA3_P!#0O\ X*M<_P#E91_:.#_Y^_@'^LF4_P#/_P# /^%_?"G_
M *&A?_!5KG_RLH_M'!_\_?P#_63*?^?_ . ?\+^^%/\ T-"_^"K7/_E91_:.
M#_Y^_@'^LF4_\_\ \ _X7]\*?^AH7_P5:Y_\K*/[1P?_ #]_ /\ 63*?^?\
M^ ?\+^^%/_0T+_X*M<_^5E']HX/_ )^_@'^LF4_\_P#\ _X7]\*?^AH7_P %
M6N?_ "LH_M'!_P#/W\ _UDRG_G_^ ?\ "_OA3_T-"_\ @JUS_P"5E']HX/\
MY^_@'^LF4_\ /_\  /\ A?WPI_Z&A?\ P5:Y_P#*RC^T<'_S]_ /]9,I_P"?
M_P" ?\+^^%/_ $-"_P#@JUS_ .5E']HX/_G[^ ?ZR93_ ,__ , _X7]\*?\
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MX!_K)E/_ #__  #_ (7]\*?^AH7_ ,%6N?\ RLH_M'!_\_?P#_63*?\ G_\
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M'^LF4_\ /_\  /\ A?WPI_Z&A?\ P5:Y_P#*RC^T<'_S]_ /]9,I_P"?_P"
M?\+^^%/_ $-"_P#@JUS_ .5E']HX/_G[^ ?ZR93_ ,__ , _X7]\*?\ H:%_
M\%6N?_*RC^T<'_S]_ /]9,I_Y_\ X!_PO[X4_P#0T+_X*M<_^5E']HX/_G[^
M ?ZR93_S_P#P#_A?WPI_Z&A?_!5KG_RLH_M'!_\ /W\ _P!9,I_Y_P#X!_PO
M[X4_]#0O_@JUS_Y64?VC@_\ G[^ ?ZR93_S_ /P#_A?WPI_Z&A?_  5:Y_\
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MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_
M]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#
M_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G
M_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @
M_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&
M5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G
M_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ
M!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQ
MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_
M]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#
M_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G
M_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @
M_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&
M5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G
M_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ
M!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQ
MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_
M]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#
M_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G
M_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @
M_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&
M5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G
M_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ
M!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQ
MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_
M]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#
M_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G
M_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @
M_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&
M5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G
M_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ
M!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQ
MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_
M]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#
M_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G
M_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @
M_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&
M5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G
M_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ
M!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQ
MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_
M]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#
M_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G
M_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @
M_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&
M5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G
M_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ
M!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQ
MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P C[H?J*^BAU/T<95@% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
: % !0 4 % !0 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
